CJC-1295 with DAC vs MK-677
Well Studied vs Well Studied
avoid Researched · 95% Both provide continuous GH elevation; combination risks excessive levels.
Molecular Data
CJC-1295 with DAC MK-677
Weight 3,647.28 Da 624.77 Da
Half-life 6-8 days ~24 hours
Chain 30 amino acids —
Type GHRH analog with DAC Non-peptide ghrelin receptor agonist
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
MK-677
Start 12.5mg daily, increase to 25mg based on tolerance / Once daily, preferably at bedtime on empty stomach
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
Research Evidence
CJC-1295 with DAC MK-677
Status Well Studied Well Studied
References 4 studies 7 studies
Latest 2025 July 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.